You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Adverse drug reactions and complications
Topical brinzolamide-induced ciliary body effusion with secondary angle closure and myopic shift
  1. Chelsea Guymer and
  2. Anna Galanopoulos
  1. Ophthalmology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
  1. Correspondence to Dr Chelsea Guymer; chelsea.guymer{at}sa.gov.au

Abstract

Here, we describe a rare case of drug-induced unilateral ciliary body effusion precipitated by topical brinzolamide, presenting acutely with pain, angle closure and myopic shift.

Ciliary body effusion was suspected clinically and confirmed by ultrasound biomicroscopy. Brinzolamide was ceased, atropine instilled and the ciliary body effusion promptly resolved without need for further treatment. Brinzolamide is a sulfonamide-derived carbonic anhydrase inhibitor (CAI) commonly used in the treatment of glaucoma. Sulfite derivates can rarely cause ciliary and suprachoroidal effusions, so if ocular pain or visual changes develop, these need to be promptly assessed.

  • Eye
  • Glaucoma

https://doi.org/10.1136/bcr-2022-253390

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms and critical revision for important intellectual content: AG and CG. The following authors gave final approval of the manuscript: AG and CG.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.